Remdesivir - COVID-19 Clinical Trial
Current COVID-19 Clinical Trial

Remdesivir

Explore
    Add a header to begin generating the table of contents

    Finding a safe and effective vaccine for the treatment of COVID-19 will take at least a year to 18 months. In the meantime, patients need treatment now during this global pandemic. The quickest way to find treatment is to test therapeutic products that are already developed and have potential to treat this particular coronavirus. 

    Remdesivir is an anti-viral delivered intravenously that works by inhibiting the replication of a virus and was developed by Gilead Sciences to treat patients after the 2014 Ebola outbreak. This treatment for Ebola was abandoned in favor of other products, including vaccines, and its use was never approved by the FDA for any indication. As an experimental anti-viral drug, scientists continued to test how remdesivir performed against other viruses. Pre-clinical tests have shown that remdesivir is effective in treating Middle East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS). The viruses behind SARS and MERS are in the same coronavirus family as COVID-19. 

     A lack of treatment options for COVID-19 allowed remdesivir to be used through expanded access, commonly referred to as “compassionate use.” This pathway allows for an unapproved drug to be used to treat seriously ill patients when no other treatments are available. Remdesivir has been reported to successfully treat the first case of COVID-19 in the U.S. Emergency access to this promising treatment was made globally available to treat hundreds of patients.  

    There remains no concrete evidence that proves remdesivir is not only effective in treating COVID-19 patients but also safe for patients to take, especially vulnerable patients such as children and the elderly. The gold standard for making this determination is through performing a randomized, placebo-controlled clinical study.  

    On February 4th, clinical trials for remdesivir as treatment for COVID-19 began in China. There are now 5 clinical trials taking place to evaluate the safety and effective of remdesivir in participant with COVID-19. Enrollment in a clinical trial is the primary way to receive this potentially beneficial drug. Results of some of these trials may be available as early as April.  

    Clinical studies are taking place in multiple clinical research locations. For more information on a study or to find a location near you please visit clinicaltrials.gov

    Below is a list of the available clinical studies. 

    Antiviral Activity of Remdesivir in Participants with Severe Coronavirus Disease

    ClinicalTrials.gov Identifier: NCT04292899 

    Description: 400 participants diagnosed with COVID-19, 18 years or older, will be randomized to two different regimens of remdesivir treatment, either a 5-day or 10-day treatment at a daily 200mg dose. 

    Study to Evaluate the Safety and Antiviral Activity of Remdesivir

    ClinicalTrials.gov Identifier: NCT04292730 

    Description: 600 participants diagnosed with COVID-19, 18 years or older, will be randomized to three different treatment arms. Placebo treatment, or remdesivir at a 5-day 200mg dose or a 10-day 100mg dose. 

    Severe 2019-nCoV Remdesivir RCT 

    ClinicalTrials.gov Identifier: NCT04257656 

    Description: 453 participants diagnosed with COVID-19, 18 years or older, will be randomized to two different treatment arms, either placebo, or remdesivir. 

    Mild/Moderate 2019-nCoV Remdesivir RCT 

    ClinicalTrials.gov Identifier: NCT04252664 

    Description: 308 participants diagnosed with COVID-19, 18 years or older, will be randomized to two different treatment arms, either placebo, or remdesivir. 

    Expanded Access Remdesivir

    ClinicalTrials.gov Identifier: NCT04302766 

    Description: Patients treated under expanded access of “compassionate use” are being followed up with to determine if remdesivir was safe and effective.

    Share this:
    Share on facebook
    Facebook
    Share on twitter
    Twitter
    Share on linkedin
    LinkedIn
    Share on reddit
    Reddit
    Share on email
    Email
    Scroll to Top

    Your choice regarding cookies on this site

    We use cookies to optimize site functionality and give you the best experience. Necessary cookies enable core functionality. The website cannot function properly without these cookies and can only be disabled by changing your browser preferences.

    For more detailed information on the cookies we use, please check our Privacy Policy.

    By continuing to access this website you are giving us consent to collect cookies.

    Want to stay informed?

    With an ever-changing situation like COVID-19, it’s important to stay as tuned in as possible. Submit your information below so we can send you periodic updates.